Exclusive interview for SPINOFF.COM with Dr. Ana Cristóvão, Founder of NeuroSoV, about neurological diseases like Parkinson’s, Alzheimer's and stroke. Currently, NeuroSoV focuses on testing small molecules with therapeutic potential for Parkinson disease. The continuous aging of population offers the market space to grow and a consistent base of potential consumers. With this perspective, the investment by academia and pharma companies in the development of new drugs for Parkinson’s disease will grow, representing a great opportunity of new customers for NeuroSoV. It aims to increase its potential business to other neurological disorders, like Alzheimer's Disease and stroke. NeuroSoV is dedicated to evaluating preclinical neurotoxicity and the effectiveness of screening solutions for drugs for Parkinson’s and other ND diseases. The company already has several international clients in the area of the pharmaceutical industry.